Risultati per: Ancora su FANS e rischio cardiovascolare

Apportare cambiamenti nello stile di vita

Studio, dimostrata l’efficacia di un test predittivo nelle donne

Se così si recuperano le ore di sonno perse durante la settimana

Studio, specie nei giovani senza fattori di rischio

Secondo la valutazione del Centro di coordinamento di emergenze

Tutto l’equipaggio è in quarantena, nessuno può sbarcare

Scoperto un meccanismo molecolare che ne aumenta la frequenza

Tra giugno e luglio 19 casi importati in Europa, 5 in Italia

Il direttore dei Trapianti della Città salute di Torino: “pericolo necrosi”

A 6 anni fabbisogno pari a zero,oltre 1500 iniziano corso laurea

Da colesterolo a perdita di vista e udito

Costi insostenibili per molti,fino a 48mila euro per tumore seno

Nei pazienti con eccesso di peso riduce il rischio di infarto e ictus

Objectives
We sought to extrapolate the long-term costs and clinical impacts attributed to the rugby fans in training–New Zealand (RUFIT-NZ) trial in Aotearoa, New Zealand.

Design
A modelled cost-effectiveness analysis using efficacy data from RUFIT-NZ was conducted from the Aotearoa New Zealand healthcare perspective.

Setting
A Markov cohort model was constructed with a lifetime time horizon. The model simulated events of myocardial infarction (MI), stroke and type 2 diabetes mellitus (T2DM) occurring among a hypothetical cohort of 10 000 individuals receiving either the RUFIT-NZ intervention or no intervention. Efficacy data were based on the RUFIT-NZ trial, and the latest Global Burden of Disease study was used to extrapolate the impact of body weight reduction on clinical outcomes of T2DM, MI or stroke. Cost and utility data were drawn from the RUFIT-NZ trial and published sources.

Primary outcome measures
The incremental cost-effectiveness ratio (ICER).

Results
Over a lifetime time horizon, participants in the RUFIT-NZ intervention gained 0.02 (discounted) quality-adjusted life years (QALYs) at an additional cost of NZ$863, relative to no intervention. The estimated ICER was NZ$49 515 per QALY gained (discounted), which is above the arbitrary willingness-to-pay threshold of NZ$45 000 per QALY. Sensitivity analyses supported the robustness of these findings.

Conclusions
RUFIT-NZ was associated with a reduction in cardiovascular and endocrine events for overweight and obese males. However, based on conservative assumptions, RUFIT-NZ was unlikely to be cost-effective from a healthcare system perspective.

Trial registration number
ACTRN12619000069156.

Confindustria: “causerà una crisi irrevesibile”. Giani: “così abbassiamo l’Irpef”